Journal article
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases
M Itchins, H Ainsworth, M Alexander, S Dean, D Dharmaraj, N Pavlakis, SJ Clarke, C Brown, J Torres, A Saqib, R Ladwa, K O'Byrne, M Moore, PY Yip, B Solomon, T John, S Kao, P Mitchell, S Parakh
Clinical Lung Cancer | Published : 2022
Abstract
Background: There are limited real world data on the IMpower150 regimen in oncogene driven tumors and central nervous system metastases; this study aims to address this gap. Materials and Methods: Retrospective analysis of patients with advanced non-small cell lung cancer treated with the IMpower150 regimen across 12 Australian sites between July 2018 and April 2021. Clinicopathologic and treatment parameters were correlated with efficacy and toxicity. Results: A total of 106 patients identified with median follow up of 8 months (range 0-72). Median age was 61 years (range 33-83), 34% Asian and 58% never-smokers. An oncogene was reported in 94 (89%) patients, EGFR in 72 (68%). At treatment c..
View full abstract